Amrecibart
Monoclonal antibody
Also known as REGN9933
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other Factor XI drugs
Cenvacibart, SHR-2004, Gruticibart, SRSD107. Compare all 5 Factor XI drugs
4 other tracked programmes target this mechanism, 4 of them ahead of this one.
This drug's own stage for Stroke Prevention in Atrial Fibrillation: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Amrecibart: this drug | Stage not on record | Monoclonal antibody | Factor XI | not yet graded | No reviewed efficacy summary in this indication | |
| Cenvacibart | Phase 3(overall) | Monoclonal antibody | Factor XI | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| SHR-2004 | Phase 3(overall) | Undisclosed | Factor XI | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Gruticibart | Phase 2(overall) | Monoclonal antibody | Factor XI | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| SRSD107 | Phase 2(overall) | RNA / oligonucleotide | Factor XI | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Milvexian | Phase 1(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Abelacimab | —(overall) | Monoclonal antibody | Factor XI/XIa (FXI/FXIa) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Amrecibart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.